

Venue of the Congress

Grand Hotel Oriente

Via Armando Diaz, 44, 80134 Napoli, Italy



Major meeting sponsor



Agilent Technologies



ThermoFisher
SCIENTIFIC

Meeting sponsor

AMGEN

Segreteria AIOM



Via Enrico Nöe, 23 - 20133 Milano
tel. 02 70630279 - fax 02 2360018
aiom.segretario@aiom.it - www.aiom.it

Segreteria Organizzativa



Via Enrico Nöe, 23 - 20133 Milano
Tel. 02 26683129 Fax. 02 59610555
info@aiomservizi.it
Provider ECM n. 1462



Associazione Italiana di Oncologia Medica



International Quality Network for Pathology

10TH MEETING ON
**EXTERNAL QUALITY
ASSESSMENT
IN MOLECULAR
PATHOLOGY**

OFFICIAL ANNUAL MEETING OF IQN PATH

Grand Hotel Oriente • 13-14 May 2022, Naples, Italy



PROGRAM



FRIDAY, MAY 13, 2022

09.00	Welcome and opening <i>A. Bianchi, N. Normanno, F. Perrone, A. Ryska</i>
09.30 - 11.00	The status of biomarker testing in Europe <i>Chairs: F. De Lorenzo, N. Normanno, A. Ryska</i>
09.30	The evolution of molecular pathology in Europe (<i>A. Ryska</i>)
09.45	Access to precision therapies in Europe (<i>R. Giuliani</i>)
10.00	The current status of biomarker testing in Europe (<i>N. Normanno</i>)
10.15	The limits to access to precision medicine: the patients' point of view (<i>K. Apostolidis</i>)
10.30	Panel discussion
11.00 - 11.30	Coffee break
11.30 - 13.00	Emerging biomarkers (Session 1): Gene fusions <i>Chair: S. Patton</i>
11.30	NTRK (<i>A. Sartore Bianchi</i>)
11.45	RET (<i>G. Curigliano</i>)
12.00	FGFR (<i>L. Rimassa</i>)
12.15	The IQN Path EQA scheme for fusions (<i>S. Patton</i>)
12.30	Discussion
13.00 - 14.30	Lunch
14.30 - 16.00	PD-L1 Testing: Current state and future developments <i>Chairs: J. Hughes, E. Torlakovic</i>
14.30	Deconstructing PT for PD-L1: Purpose-based EQA (<i>J. Hughes</i>)
14.45	Report on CBQA/IQN Path digital slide PD-L1 initiative (<i>E. Torlakovic</i>)
15.00	CAP-ACP Guidelines for PD-L1 testing: Relevance to PT (<i>C. Cheung</i>)

15.30 - 16.00 **Report on current PD-L1 modules from Academic Members:**

15.30	CAP (<i>E.C. Zongming</i>)
15.40	DGP/QuIP (<i>K. Jöhrens</i>)
15.50	UK NEQAS (including RCPAQAP results) (<i>S. Parry</i>)

16.00 - 17.00 **Technology improvements**
Chair: N. Normanno

17.00 - 17.15 Tea break

17.15 - 18.30 **General Meeting of IQN Path**
All IQN Path Academic and Corporate Members are invited to participate

SATURDAY, MAY 14, 2022

09.00 - 10.00 **The role of liquid biopsy in the diagnostic path of cancer patients**
Chair: S. Deans

09.00	The IALSC recommendations for liquid biopsy testing (<i>C. Rolfo</i>)
09.15	The ESMO recommendations for liquid biopsy testing in clinical practice (<i>P. Hofman</i>)
09.30	The IQN Path EQA scheme for liquid biopsy (<i>S. Deans</i>)
09.45	Discussion on next steps

10.00 - 11.15 **Emerging biomarkers (Session 2): HRD**
Chair: E. Rouleau

10.00	PARP inhibitors and HRD in ovarian cancer (<i>E. Pujade Lauraine</i>)
10.15	Current status of PARP inhibitors beyond ovarian cancer (<i>G. Daniele</i>)
10.30	The MITO-MANGO initiative for HRD testing (<i>S. Marchini</i>)
10.45	Discussion: Focus on development of an IQN Path EQA initiative

11.15 - 11.45 Coffee break

11.45 - 13.00 **IQN Path future projects**
Session restricted to IQN Path partners

13.00 - 14.00 Lunch